ASSESSMENT OF RESPONSE TO LOMUSTINE-TEMOZOLOMIDE CHEMOTHERAPY IN ADDITION TO RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA USING FET PET

被引：0

作者：

Werner, J. ^{[1
,2
]}

Wollring, M. M. ^{[1
,2
]}

Tscherpel, C. ^{[1
,2
,3
]}

Rosen, E. K. ^{[1
,2
]}

Ceccon, G. ^{[1
,2
]}

Stetter, I ^{[1
,2
]}

Lohmann, P. ^{[4
,5
]}

Weller, J. ^{[6
]}

Stoffels, G. ^{[4
]}

Baues, C. ^{[7
,8
]}

Celik, E. ^{[7
,8
]}

Mottaghy, F. M.

Goldbrunner, R. ^{[2
,9
]}

Herrlinger, U.

Fink, G. R. ^{[1
,2
,4
]}

Langen, K. ^{[4
]}

Galldiks, N. ^{[1
,2
,4
,5
]}

机构：

[1] Univ Cologne, Fac Med, Dept Neurol, Cologne, Germany

[2] Univ Cologne, Univ Hosp Cologne, Cologne, Germany

[3] Goethe Univ, Univ Hosp Frankfurt, Dept Neurol, Frankfurt, Germany

[4] Res Ctr Juelich, Inst Neurosci & Med INM 3 INM 4, Julich, Germany

[5] RWTH Univ Hosp, Dept Nucl Med, Aachen, Germany

[6] Univ Hosp Bonn, Ctr Neurol, Dept Neurooncol, Bonn, Germany

[7] Ruhr Univ Bochum, Marien Hosp Herne, Fac Med, Dept Radiat Oncol, Bochum, Germany

[8] Ruhr Univ Bochum, Univ Hosp, Marien Hosp Herne, Bochum, Germany

[9] Univ Cologne, Fac Med, Dept Gen Neurosurg, Cologne, Germany

来源：

NEURO-ONCOLOGY | 2024年 / 26卷

关键词：

D O I：

10.1093/neuonc/noae144.162

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P09.03.B

引用

页码：V50 / V50

页数：1

共 50 条

[41] COST-EFFECTIVENESS OF FET PET FOR EARLY TREATMENT RESPONSE ASSESSMENT IN GLIOMA PATIENTS FOLLOWING ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY
Rosen, J.
Ceccon, G.
Bauer, E. K.
Werner, J. M.
Kabbasch, C.
Fink, G. R.
Langen, K. J.
Galldiks, N.
NEURO-ONCOLOGY, 2021, 23 : 46 - 46
[42] Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine
Galldiks, Norbert
Dunkl, Veronika
Ceccon, Garry
Tscherpel, Caroline
Stoffels, Gabriele
Law, Ian
Henriksen, Otto M.
Muhic, Aida
Poulsen, Hans S.
Steger, Jan
Bauer, Elena K.
Lohmann, Philipp
Schmidt, Matthias
Shah, Nadim J.
Fink, Gereon R.
Langen, Karl-Josef
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (13) : 2377 - 2386
[43] Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine
Norbert Galldiks
Veronika Dunkl
Garry Ceccon
Caroline Tscherpel
Gabriele Stoffels
Ian Law
Otto M. Henriksen
Aida Muhic
Hans S. Poulsen
Jan Steger
Elena K. Bauer
Philipp Lohmann
Matthias Schmidt
Nadim J. Shah
Gereon R. Fink
Karl-Josef Langen
European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 2377 - 2386
[44] Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial
Weller, Johannes
Tzaridis, Theophilos
Mack, Frederic
Steinbach, Joachim Peter
Schlegel, Uwe
Hau, Peter
Krex, Dietmar
Grauer, Oliver
Goldbrunner, Roland
Baehr, Oliver
Uhl, Martin
Seidel, Clemens
Tabatabai, Ghazaleh
Brehmer, Stefanie
Bullinger, Lars
Galldiks, Norbert
Schaub, Christina
Kebir, Sied
Stummer, Walter
Simon, Matthias
Fimmers, Rolf
Coch, Christoph
Glas, Martin
Herrlinger, Ulrich
Schaefer, Niklas
LANCET ONCOLOGY, 2019, 20 (10): : 1444 - 1453
[45] Phase II Trial of Hypofractionated Intensity Modulated Radiotherapy to 60 Gy in 10 Fractions with Temozolomide Chemotherapy for Patients with Newly Diagnosed Glioblastoma Multiforme
Reddy, K.
Damek, D.
Gaspar, L.
Ney, D.
Kavanagh, B.
Waziri, A.
Lillehei, K.
Stuhr, K.
Chen, C.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S130 - S130
[46] FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status
Niyazi, Maximilian
Schnell, Oliver
Suchorska, Bogdana
Schwarz, Silke Birgit
Ganswindt, Ute
Geisler, Julia
Bartenstein, Peter
Kreth, Friedrich-Wilhelm
Tonn, Joerg-Christian
Eigenbrod, Sabina
Belka, Claus
la Fougere, Christian
RADIOTHERAPY AND ONCOLOGY, 2012, 104 (01) : 78 - 82
[47] RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study
Christoph P Beier
Christina Schmid
Thierry Gorlia
Christine Kleinletzenberger
Dagmar Beier
Oliver Grauer
Andreas Steinbrecher
Birgit Hirschmann
Alexander Brawanski
Christopher Dietmaier
Tanja Jauch-Worley
Oliver Kölbl
Torsten Pietsch
Martin Proescholdt
Petra Rümmele
Armin Muigg
Günther Stockhammer
Monika Hegi
Ulrich Bogdahn
Peter Hau
BMC Cancer, 9
[48] RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study
Beier, Christoph P.
Schmid, Christina
Gorlia, Thierry
Kleinletzenberger, Christine
Beier, Dagmar
Grauer, Oliver
Steinbrecher, Andreas
Hirschmann, Birgit
Brawanski, Alexander
Dietmaier, Christopher
Jauch-Worley, Tanja
Koelbl, Oliver
Pietsch, Torsten
Proescholdt, Martin
Ruemmele, Petra
Muigg, Armin
Stockhammer, Guenther
Hegi, Monika
Bogdahn, Ulrich
Hau, Peter
BMC CANCER, 2009, 9 : 308
[49] AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.
Chinot, O. L.
Wick, W.
Saran, F.
Mason, W. P.
Henriksson, R.
Nishikawa, R.
Zeaiter, A. H.
Moore, N.
Das, A.
Cloughesy, T. F.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[50] Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study
Franceschi, Enrico
Depenni, Roberta
Paccapelo, Alexandro
Ermani, Mario
Faedi, Marina
Sturiale, Carmelo
Michiara, Maria
Servadei, Franco
Pavesi, Giacomo
Urbini, Benedetta
Pisanello, Anna
Crisi, Girolamo
Cavallo, Michele A.
Dazzi, Claudio
Biasini, Claudia
Bertolini, Federica
Mucciarini, Claudia
Pasini, Giuseppe
Baruzzi, Agostino
Brandes, Alba A.
JOURNAL OF NEURO-ONCOLOGY, 2016, 128 (01) : 157 - 162

← 1 2 3 4 5 →